Application 1043
Recombinant human thyroid stimulation hormone (rhTSH) diagnostic agent for use in well-differentiated thryoid cancer
| Application No. | 1043 |
| Application Name | Recombinant human thyroid stimulation hormone (rhTSH) diagnostic agent for use in well-differentiated thryoid cancer |
| Advisory Panels | Mr Stephen Blamey (Chair and MSAC member) Professor Bruce Barraclough (MSAC member) Dr Michael Kitchener (MSAC member) Dr Roger Allison (Royal Australian and New Zealand College of Radiologists nominee) Professor Leigh Delbridge (Royal Australasian College of Surgeons nominee) Dr Bruce Robinson (Endocrine Society nominee) Dr Monica Rossleigh (Australia and New Zealand Association of Physicians in Nuclear Medicine nominee) Ms Catherine Thompson (Consumers' Health Forum of Australia nominee) |
| Date Received by MSAC Secretariat | 17 April 2001 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | This assessment was considered by the MSAC at the 21 August 2002 meeting. The MSAC recommended that on the strength of evidence pertaining to the diagnostic use of recombinant thyroid-stimulating hormone in well-differentiated thyroid cancer, public funding should be supported for this procedure only in patients in whom THT withdrawal is medically contraindicated. In addition, on the basis of the current evidence, both rhTSH-stimulated whole body scanning and serum Tg testing should be undertaken concurrently. The MSAC recommends that public funding for rhTSH should not be supported in patients who are able to tolerate THT withdrawal, on the basis of lower diagnostic sensitivity and a high cost-effectiveness ratio. |
| Stage 4 - Decision | Endorsed by the Minister for Health and Ageing 16 October 2002 |
| Stage 5 - Implementation |  |